News
2024.06.07
| Possibilities for Expansion and Collaboration Beyond Genetic Analysis Services
DXVX announced on the 7th that it has signed a strategic cooperation agreement with Malaysia's MGRC Therapeutics for comprehensive business collaboration in Malaysia. The agreement aims to solidify the partnership between the two companies in advance of signing a supply contract for DXVX's genome analysis services. The primary focus is on the mutual interests related to the service supply contract, with expectations for broad cooperation involving various technologies owned by DXVX beyond genome analysis services.
MGRC, listed on the Malaysian stock exchange and founded in 2010, oversees four subsidiaries, including MGRC Therapeutics. The company is particularly active in promoting advanced medical technologies domestically, such as CAR-T immunotherapy.
Through this contract, DXVX plans to establish a foothold in the Asian and global markets, including Malaysia, and discuss various cooperation plans in other business areas such as in vitro diagnostics and digital healthcare to expand service offerings.
Azri Azerai, CEO of MGRC, emphasized, "The cooperation with DXVX represents our strategic shift to pioneer new paths through genome analysis. By combining the strengths of both companies, we will enhance the precision and accessibility of genome analysis, achieving significant advancements in personalized medicine."
Kwon Kyu-chan, CEO of DXVX, stated, "The strategic cooperation with MGRC Therapeutics marks an important start for DXVX to strengthen its presence in the Asian and global markets. Genome analysis is at the core of our Healthcare 4.0 vision. Through this collaboration, we will expand our genome analysis services and digital healthcare solutions to advance the field of preventive medicine."
DXVX has collected over 400,000 clinical genome analysis data through its genome analysis services, establishing the largest genome analysis database in the country and conducting medical data business utilizing this database.